This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (30)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Michael S. Lauer, MD; Phil B. Fontanarosa, MD

JAMA. 2001;285:2508-2509.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

During the past decade, there has been tremendous progress in identifying novel risk factors and precisely delineating the role of traditional risk factors associated with coronary heart disease (CHD), with substantial research advances related to the role of lipoproteins and lipid metabolism. Observational studies have established the relationship of serum cholesterol and other lipoproteins with CHD in specific subgroups.^1-3 Clinical trials have demonstrated convincing benefits of cholesterol lowering for reducing death and myocardial infarction among patients with CHD^4-5 as well as beneficial effects of cholesterol lowering for decreasing the incidence of cardiac events in patients without established coronary disease.^6-7 Accurately synthesizing and appropriately applying this rapidly accumulating evidence into clinical practice is essential for reducing the morbidity and mortality associated with coronary disease.

Thus, the Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel (Adult Treatment . . . [Full Text of this Article]

Author Affiliations: Dr Lauer is Contributing Editor and Dr Fontanarosa is Executive Deputy Editor, JAMA.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
JAMA. 2001;285(19):2486-2497.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Diet and Primordial Prevention of Cardiovascular Disease in Children and Adolescents
Daniels
Circulation 2007;116:973-974.
FULL TEXT  

Primary Care Physicians' Knowledge and Practice Patterns in the Treatment of Chronic Kidney Disease: An Upstate New York Practice-based Research Network (UNYNET) Study
Fox et al.
J Am Board Fam Med 2006;19:54-61.
ABSTRACT | FULL TEXT  

Are Remnant-Like Particles Independent Predictors of Coronary Heart Disease Incidence?: The Honolulu Heart Study
Imke et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:1718-1722.
ABSTRACT | FULL TEXT  

Long-term statin use and psychological well-being
Young-Xu et al.
J Am Coll Cardiol 2003;42:690-697.
ABSTRACT | FULL TEXT  

Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy
Grundy
Circulation 2002;106:2526-2529.
FULL TEXT  

Obesity, Metabolic Syndrome, and Coronary Atherosclerosis
Grundy
Circulation 2002;105:2696-2698.
FULL TEXT  

Aspirin for Primary Prevention of Coronary Events
Lauer
NEJM 2002;346:1468-1474.
FULL TEXT  

NCEP Guidelines for Cholesterol Management
Journal Watch Cardiology 2001;2001:1-1.
FULL TEXT